Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Accumulating data indicate that inflammation may play a role in a host of psychiatric illnesses.1 These data reveal reliable associations of inflammatory markers with psychiatric disorders, the induction of psychiatric symptoms following administration of inflammatory stimuli, the association of inflammation-related genes with psychiatric disease, and the elucidation of neurobiological and immunological mechanisms by which inflammation targets neurotransmitters and neurocircuits to change behavior. Nevertheless, whether therapeutic strategies that inhibit inflammation will be effective in treating psychiatric illnesses remains unclear. This question is not trivial given the pressing need for novel therapeutics based on the high rates of treatment resistance across disorders and on our relatively limited psychopharmacologic repertoire.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Miller AH, Raison CL. Are Anti-inflammatory Therapies Viable Treatments for Psychiatric Disorders? Where the Rubber Meets the Road. JAMA Psychiatry. 2015;72(6):527–528. doi:10.1001/jamapsychiatry.2015.22
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: